Asset

  • No.

    155

  • Asset Title

    Treatment of KRAS-Variant Cancers with Serotonin Transporter Inhibitors

  • Organization

    Yale University

  • Product Type

    Small molecule

  • Therapeutic Area

    Oncology

  • Development Stage

    Hit To Lead or Lead Optimization

  • Technical Summary

    • The KRAS variant impacts responses to various cancer therapies. Ovarian tumors with the KRAS variant are resistant to treatment with standard chemotherapies including cisplatin. 

    • EOC tumors harboring the KRAS-variant were found to be significantly more resistant to treatment with platinum than those without the KRAS-variant. There is currently no drug available to specifically treat KRA-variant ovarian cancer.

    • The method comprising administering to the subject an effective amount of a serotonin uptake inhibitor, wherein the subject comprises rs6176430 variant of the KRAS gene. 

    • The serotonin uptake inhibitor is more effective in killing a cancer cell comprising the rs61764340 variant of the KRAS gene than killing a corresponding cancer cell that doe not comprise the rs61764370 variant of the KRAS gene.

    • The serotonin uptake inhibitor is more effective in inhibiting survival of a cancer cell comprising the re61764340 variant of the KRAS gene than in inhibiting survival of a corresponding cancer cell that does not comprise the rs61764970 variant of the KRAS gene. 

    • The administration of the serotonin uptake inhibitor results in inhibition of the growth of a tumor of the cancer. 

  • Patent

    WO2021236498A1

  • Publication

  • Attachment

TOP